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Abstract
One of the most revealing parts of the human body is the eye. In fact, systemic conditions and diseases are commonly manifested 
in the eye and display pathology that reflect disorders. An example of a chorioretinal vascular condition that can present itself in 
the eye is diabetes mellitus, which if left uncontrolled can damage the eyes and a person’s vision. Age related macular degeneration 
is specific to the eye, potentially leading to irreversible loss of central vision. Intravitreal injections containing vascular endothelial 
growth factor inhibiting agents appear to be the leading lines of defense against diabetic retinopathy and macular degeneration 
progression, helping to reduce both the pathological and visual manifestations of these chorioretinal vascular diseases.
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Background
Diabetes is the fourth leading cause of health complica-
tions, making many people susceptible to diabetic reti-
nopathy. In fact, the prevalence of diabetes is expected 
to increase by 7.7% by 2030, leaving many people at risk 
(Abbas et al., 2017). Age related macular degeneration is 
another neovascular condition of the eye which can re-
duce visual acuity to 20/800 in a patient’s better eye by 
60%, resembling a patient who “is bedridden with a cata-
strophic stroke” (Folk & Stone, 2012). These diseases are 
capable of impairing the daily functioning of a patient if 
they are not treated and monitored. Most ocular diseas-
es can be identified with a dilated eye exam. Treatments 
with delivery of vascular endothelial growth factor inhib-
itors to the retina via intravitreal injection has gradually 
become the first line of treatment for ocular conditions 
such as diabetic retinopathy and macular degeneration. 
Pan-retinal photocoagulation (PRP) is a laser treatment 
that can also be used in controlling these conditions and 
preventing the progression of vision loss. Research is cur-
rently being done on both of these methods in an effort 
to determine their use in ocular disease.
Hypothesis
In most circumstances, vascular endothelial growth factor 
inhibiting medications can be implemented in a treatment 
plan to alleviate both the visual complaints and the patho-
logical findings associated with chorioretinal vascular 
conditions. In some cases, however, this treatment option 
may not be appropriate due to potential risks and anoth-
er treatment may be indicated.
Methods
Research for this paper was conducted with the use of Pro-
Quest, EBSCO, and Pub-Med databases. Figures used through-
out include corresponding sources from research articles.
Diagnostic Methods
Conditions such as age-related macular degeneration 
and diabetic retinopathy can be diagnosed with a prop-
er exam. Ophthalmic tropicamide, a mydriatic, is used in 
order to give the clinician a proper view of the fundus. 
Imaging methods such as optical coherence tomography 
(OCT), fluorescein angiography, and wide field fundus 
imaging may also be used for future comparison during 
treatment. Diagnostic guidelines have been established to 
aid in classifying the type and severity of ocular disease. 
Findings, diagnostic methods, visual complaints, and prog-
nosis of these conditions will be discussed in the following 
sections. Popular treatment options will also be outlined.
Diabetic Retinopathy
Diabetic retinopathy (DMR) is a complication resulting 
from diabetes mellitus Type 1 or 2. It appears to be one 
of the leading causes of blindness in patients aged 20-65 
(Stewart, 2012). Currently, 336 million people suffer from 
diabetes and are therefore at risk of developing diabetic 
retinopathy, otherwise known as DMR (Abbas et al., 2017). 
Diabetic damage to the eye is a result of macular edema, 
which in more advanced cases, can lead to intraocular 
bleeding, detachments of the retina, macular ischemia, and 
retinal neovascularization. Possible risk factors for DMR 
include hyperglycemia, elevated blood pressure, and ele-
vated serum levels (Buffolino & Park, 2019). Patients can 
usually control risk factors with lifestyle modifications 
including diet and exercise, yet it is important to note 
that specific patient demographics can predispose people 
to diabetic retinopathy. 
Firstly, individuals diagnosed with diabetes at an earlier 
age tend to be more vulnerable to developing the condi-
tion. DMR becomes more prevalent as the age of diabetes 
onset is younger. “What is hitherto unknown is whether 
the increased prevalence of complications associated with 
early-onset disease is simply a consequence of the lon-
ger duration of disease, a consequence of a more severe 
metabolic phenotype, or in fact something specific to the 
diabetic milieu in younger patients that makes tissues more 
inherently susceptible to hyperglycemic damage” (Wong 
et al., 2008). Long-term exposure to elevated blood glu-
cose levels seems to lead to oxidative stress on the eyes 
(Stewart, 2012). By the same token, retinopathy is not 
common in the first five years of a Type 1 diabetes onset, 
and diabetic retinopathy tends to be present after 20 years 
of having Type 2 diabetes (Cook et al., 2008). 
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Secondly, in addition to patient age, ethnicity is also 
associated with DMR. African Americans, Hispanics, and 
South Asians are especially prone to diabetic retinopathy. 
African Americans seemingly have reduced glycemic con-
trol, which can lead to retinal complications due to higher 
A1C values. The internationally recognized mark differ-
entiating safe and unsafe A1C values is 7% (Long et al., 
2017). A study showed that over a six-year period, 72% 
of African Americans with Type 1 diabetes mellitus devel-
oped retinopathy (Buffolino & Park, 2019). Furthermore, 
the combination of male sex, African American ethnicity, 
duration of standing diagnosis, and value of hemoglobin 
A1C, were “positively associated with retinopathy severi-
ty” (Long et al., 2017).
Before any signs of diabetic damage appear on the 
retina, choroidal vessels may constrict due to hypoxia 
and vascular changes can develop. Furthermore, it is im-
portant to note that in the early stages of damage to the 
retina, the patient may not be able to discern changes 
in visual acuity; the condition is usually diagnosed in a 
later stage of diabetic retinopathy (Wang & Tao, 2019). 
About 50% of patients with diabetes do not come for 
yearly screening visits (Buffolino & Park, 2019). The first 
markers of diabetic damage in the eye are the results of 
swelling and leakage of blood vessels because of poorly 
controlled blood sugar levels. The natural synthesis of 
vascular endothelial growth factors (VEGF) results in 
the disruption of the blood-retina barrier that leads to 
the spread of serum proteins leading to edema (Stewart, 
2012). Bleeding near the macula can noticeably blur the 
patient’s vision. According to Mayo Clinic’s webpage on 
diabetic retinopathy (n.d.), the patient may also complain 
of fluctuating vision. This can occur because of uncon-
trolled blood sugar levels that cause the lens to swell and 
alter the refraction of light in the eye. Two other common 
visual complaints are impaired color vision and floaters 
(Vien, n.d.). Over time, the body may begin to generate 
new blood vessels in order to properly supply the eye 
with oxygen, which severely impacts the patient’s vision 
and everyday functioning. Other lesions associated with 
diabetic retinopathy such as microaneurysms, hemor-
rhages, cotton wool spots, and hard exudates can be seen. 
Diagnosis and Prognosis of Diabetic Retinopathy
Diabetic retinopathy is classified into either proliferative 
or nonproliferative diabetic retinopathy (PDR/NPDR) 
and then further broken down into mild, moderate, and 
severe. This classification considers the degree of damage 
present on the retina. The job of the clinician is not an 
easy one to classify the stage of diabetic retinopathy. With 
the help of wide field fundus imaging, the ophthalmologist 
is able to document and compare any changes to the ap-
pearance of the retina. The wide field images below can 
demonstrate the classifications of diabetic damage to the 
retina based on any associated findings.
Additionally, optical coherence tomography (OCT) is 
used to provide cross-sectional scans of the retina which 
can also help in determining the presence and degree of 
edema or cotton wool spots. Layers of the retina such as 
the RPE and choroid may also be altered. 
Age-Related Macular Degeneration
Age related macular degeneration (AMD) is the most 
common cause of blindness in patients older than age 65. 
In industrialized countries, blindness due to AMD had a 
reported 1.47% prevalence and affected 1.75 million peo-
ple in the United States alone (Eng, et al., 2019). The depo-
sition of yellow, extracellular material underneath the 
retinal pigment epithelium that form drusen, indicative of 
photoreceptor cells that are degenerating is a key com-
ponent of AMD (Virgili et al., 2015). The RPE must reuse 
materials in order to help revitalize photoreceptors. A 
defect in the cycle suggests the poor quality of enzymes 
that are responsible for breaking down those materials 
(Sarks et al., 1994), leading to degeneration of the RPE 
as drusen evolve into geographic atrophy. Extracellular 
deposits or atrophy of the RPE near the retina can lead 
to significant loss of central vision. As the drusen degen-
erate, they give a white appearance to the retina with 
“irregular margins and foci of calcification before disap-
pearing to leave a focal patch of atrophy” (Sarks et al., 
1994). Most patients complain of blurred or distorted 
vision or a scotoma (Cook et al., 2008). Risk factors for 
AMD include smoking, hyperlipidemia, and hypertension. 
Age-related macular degeneration is also strongly tied to 
a genetic predisposition to the point that children and sib-
lings of patients with AMD are automatically considered 
suspects for the condition. Many sources rank genetics 
as an important contributor to the likelihood of devel-
oping age-related macular degeneration. Various studies 
show that people of African descent have a reduced risk 
for AMD, than does the Caucasian population (Delcourt, 
n.d.). Smoking increases the risk of AMD as well. 
Although much about AMD and its pathogenesis is still 
unknown, studies show “that the largest single genetic 
factor contributing to AMD is a variant of codon 402 in 
the gene encoding complement…[that] strongly supports 
the long-held belief that the immune system is an import-
ant contributor to AMD” (Folk & Stone, 2012). In some 
observed cases of AMD, inflammatory mediators and 
other molecules have been found at the macula, indicating 
that there is indeed a connection between the condition 
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and inflammation. Furthermore, the release of excess ac-
tivated macrophages in chronic inflammatory diseases is 
linked to cellular damage at the macula. Electron micros-
copy and immunohistochemistry methods were used to 
detect the presence of inflammatory biomarkers at sites 
of atrophy and neovascularization in patients with AMD 
(Cachulo & Costa, 2017).
Prognosis and Classification of AMD
Age-related macular degeneration is diagnosed with 
a dilated retinal examination. Evaluating a case of AMD 
requires paying attention to changes at or near the mac-
ula. Age-related macular degeneration begins with the 
dry form, characterized by the presentation of drusen. 
Number, size, and location of drusen are helpful in de-
termining the progression of the condition. Additionally, 
drusen with indistinct borders seem to be indicative of 
the advancement of AMD (Cachulo & Costa, 2017). 
As AMD progresses, the retinal pigment epithelium 
layer begins to show signs of atrophy. A case of AMD is 
characterized as wet or neovascular once new blood ves-
sels begin to grow over or underneath the RPE (Folk & 
Stone, 2012). The generalized term “late AMD” refers to 
two specific presentations on the macula with exudates 
which can either be geographic atrophy or vascular AMD. 
Progression from dry to wet AMD occurs for 15% of 
patients complaining of severe loss of central vision and 
presenting with geographic atrophy that develops (Eng et 
al., 2019). Patients may notice visual distortion of straight 
lines. Ten percent of patients with AMD suffer from this 
more advanced form. More than 200,000 patients in the 
United States alone are diagnosed per year, accounting 
for 90% of all severe vision loss (Stewart, 2012). In a large 
study done, “the prevalence of large drusen increased 
from about 1.5% in Caucasians aged 40-49 years, to more 
than 25% in those aged 80 years or more” (Delcourt, 
n.d.). This statistic is important to consider because it 
indicates that Caucasians appear to be more at risk for 
developing AMD than people of other demographics such 
as Hispanic American, African American, and Chinese 
(Delcourt, n.d.). Of course, as the name of the condition 
suggests, the likelihood of developing AMD increases ex-
ponentially with age.
VEGF in Ophthalmology
Angiogenesis is a process that can be both lifesaving 
and necessary, yet in some cases can be detrimental. 
Throughout the body, the natural process for generating 
new blood vessels is crucial for maintenance related to 
growth (embryonic or otherwise) and repair. Yet in cir-
cumstances of hypoxia and inflammation, it allows the 
growth of tumors and is linked to the destruction of tis-
sue (Stewart, 2012). Angiogenesis is also important when 
neovascularization is required such as after myocardial 
infarction. However, in ophthalmic cases, the generation 
of new blood vessels can lead to hyperpermeability that 
can harm vision by leading to retinal detachments and 
edema between the retinal layers. The primary molecule 
that is associated with angiogenesis is vascular endothelial 
growth factor. “Within the posterior segment of the eye, 
VEGF is produced by retinal pigment epithelial cells, neu-
rons, glial cells, endothelial cells, ganglion cells, Muller cells, 
and smooth muscle cells” (Stewart, 2012). The primary 
cells of interest leading to the harms from AMD and DMR 
however, are vascular endothelial cells. Generally, the syn-
thesis of VEGF is triggered by tissue hypoxia that can ei-
ther be caused by “primary vascular occlusive disease or 
anaerobic tumor metabolism” (Stewart, 2012). The mech-
anism leading to the proliferation of vessels is complex 
but it results in mitosis and swelling of the endothelial 
cells, as well as vasodilation, helping new blood vessels 
develop. Specifically, VEGF works to encourage growth 
along the endothelial cells and dissolve the spaces be-
tween them, leading to the breakdown of the blood-reti-
nal barrier that makes capillaries leak and new, potentially 
detrimental, blood vessels form (Stewart, 2012). VEGF-A, 
a subfactor of this molecule, is linked to growth and 
permeability of newly-developing blood vessels. VEGF 
inhibitors block the receptors that natural VEGF would 
bind to, preventing angiogenesis. “Long-term blockade of 
VEGF-A [receptor] causes shrinkage and maturing of the 
vessels so that they no longer leak. The accumulation of 
fluid within and beneath the retina dissolves, and the pho-
toreceptors reattach to the underlying retinal pigment 
epithelium” (Folk & Stone, 2012). By using a medication 
that reduces the permeability of the retinal vessels and 
stopping their growth, leakage is also reduced, preventing 
swelling in order to bring the patient’s visual acuity back 
to baseline (Folk & Stone, 2012). It is interesting to note 
that these drugs are capable of resolving findings asso-
ciated with two very different conditions in that one is 
systemic and can target multiple parts of the body, while 
the other is localized in the eye.
VEGF Inhibitors: A Comparison
Although all VEGF inhibitors prevent neovascularization, 
there are several subclasses of this drug. Their generic 
names aflibercept, bevacizumab, and ranibizumab will be 
used throughout this paper (Folk & Stone, 2012). The ef-
ficacy of the medications as they compare to each other 
is still being studied.
Bevacizumab received approval from the Food and 
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Drug Administration for the treatment of colon cancer. 
Bevacizumab also binds to VEGF-A, which led clinicians to 
think that the drug may also be effective in treating neo-
vascularization and exudates on the retina. Although there 
is no FDA approval for its intravitreal use, bevacizumab is 
proving itself effective (Folk & Stone, 2012). When com-
pared to other medications in its class, bevacizumab has 
a longer half-life. One dose of the drug can reduce levels 
of natural VEGF in the blood by 117 times in just one day 
and when measured after one month, still maintained a 
four-fold reduction (Stewart, 2012). Furthermore, many 
clinicians recommend this drug because of its vast dif-
ference in cost compared to others. Being prepared in 
larger doses than is necessary for the eye means that the 
medication can be divided for multiple doses (1.25 mg. 
on average), reducing the cost even further. Whereas a 
dose of ranibizumab costs $2000, bevacizumab, although 
regarded as off label therapy, costs $75 per treatment 
(Folk & Stone, 2012). 
Ranibizumab was developed specifically for use in the 
eye by fragmenting the bevacizumab molecule for higher 
affinity by five to twenty times more than bevacizumab 
(Stewart, 2012). A study looking at regular monthly treat-
ment with ranibizumab shows that the first five years of 
treatment produce the best results in terms of visual acu-
ity, but then results seem to approach baseline levels over 
time thereafter (Nishikawa et al., 2019). For treatment with 
ranibizumab, the MARINA study attempted to determine 
effective dosage of the medication. At random, 716 pa-
tients with neovascular AMD were treated with monthly 
0.3mg or 0.5mg injections of the drug, or sham treatment 
for 24 months. Results showed that 92% of patients that 
were treated with 0.3mg of ranibizumab and 90% treated 
with 0.5mg lost less than 15 letters when being tested for 
changes in visual acuity. Furthermore, 26.1% of patients 
that were treated with 0.3mg and 33.3% with 0.5mg treat-
ment had a 15-letter improvement or greater. 
When aflibercept is compared to the other drugs, its 
increased binding affinity to VEGF-A receptors combined 
with its larger molecular size allows for a higher efficacy 
and hence, less frequent treatment. When used on a two-
month basis after three monthly consecutive loading doses, 
results compared to monthly treatment with ranibizumab 
(Stewart, 2012). Patients with neovascular AMD who were 
treated with aflibercept intraocular injections were able to 
sustain improved vision for four years. Even though after 
one year some regression was present, 94.5% of patients 
still had improved vision. “Thus, visual gain [of aflibercept] 
in the first year is generally favorable, but long-term out-
come is not as promising” (Nishikawa et al., 2019).
Conclusively, visual acuity was shown to improve with all 
three classes of treatment, but specific data was shown by 
a study conducted by DRCR.net in which 600 Americans 
with diabetic edema participated. The average age was 61 
and most people had diabetes for over 15 years. Visual 
acuity before the study was 20/32 or worse and patients 
were administered either of the three drugs at random 
and monitored on a monthly basis in the first year of the 
study. When comparing the visual acuity of patients after 
treatment, those on aflibercept for two years were able 
to read 3.5 more lines compared to ranibizumab patients 
who read 3, and bevacizumab patients read 2.5 (Wells, 
2016). Aflibercept showed better efficacy after the one- 
and two-year mark. “By two years, 41 percent of partic-
ipants in the aflibercept group received laser treatment 
to treat their macular edema, compared with 64 percent 
of participants in the bevacizumab group and 52 percent 
in the ranibizumab group.” Ultimately, with treatment in-
volving any of the three drugs, visual acuity was improved 
to 20/32 and 20/40. There were even studies showing the 
efficacy of bevacizumab in improving patients’ visual acui-
ty from 20/235 to 20/172. The results of the study suggest 
that there is a slight difference between the frequencies 
at which the drug must be readministered depending on 
the specific type of medication chosen. According to the 
DRCR study done, there was no significance to using one 
medication over another for treatment of mild macular 
edema when visual acuity is 20/40 or better. However, 
in cases of 20/50 or worse vision it has been shown that 
Eylea (aflibercept) performed better than ranibizumab 
and bevacizumab (Wells, 2016).
Risks
Although this modality of treatment is usually the first 
line of defense against further damage to the retina, exist-
ing risks should be considered. Firstly, for all the subclass-
es of intravitreal injections used for treating chorioretinal 
disorders, the risk for eye infection and inflammation is 
the same. These are consequences of the administration 
and not the drug itself (Wells, 2016). Injection into the 
vitreous chamber also raises the risk for endophthalmi-
tis, retinal tear or detachment at the area of injection, 
and vitreous hemorrhage because of penetrative trauma 
(Pershing et al., 2013). These risks must be kept in mind 
when developing a treatment plan for a patient suffering 
with other kinds of ocular disease as well. Furthermore, 
because additional fluid is added to the vitreous cavity 
when the medication is given, an elevation in intraocular 
pressure from increased volume in the eye can result.
A study was done spanning academic centers Stanford 
University Hospital & Clinics and Mayo Clinic. Patients 
who received anti-VEGF injections between January 1, 
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2006 and December 31, 2010 participated in order to 
determine the relationship between administration of 
the drug and intraocular pressure elevation taking place 
within 60 days of the injection. Intraocular pressure 
asymmetry between the eyes by a value of more than 
3mm Hg was also considered. Those with a history of 
glaucoma or elevated IOP in the past did not qualify to 
participate. “A total of 11,828 bevacizumab injections and 
10,354 ranibizumab injections were administered during 
the study period at the two clinical sites. In this series, 21 
eyes of 18 patients developed elevated IOP of 24mm Hg 
of higher within 60 days of previous injection” (Pershing 
et al., 2013). Most patients were Caucasian females who 
received treatment for wet AMD and presented other 
pathology related to elevated IOP, such as narrow ante-
rior chamber angles on gonioscopy. Most of the 21 eyes 
needed treatment for elevated pressure, 76% required 
prolonged treatment, and 19% resolved with no treat-
ment. It was found that a risk of increase in IOP persisted 
even later in treatment after multiple injections to the 
eye. This risk was reported regardless of the subclass of 
anti-VEGF used, however a higher chance of IOP eleva-
tion in ranibizumab treatment was reported (Pershing et 
al., 2013). This risk is especially important to consider if 
the patient in question has glaucoma or is a glaucoma 
suspect, as a subtle rise in intraocular pressure may be 
detrimental. In such a case, the drug should be adminis-
tered and the patient carefully monitored for changes in 
IOP that may lead to an acute attack of glaucoma.
Additionally, receiving anti-VEGF drugs alongside having 
coexisting cardiovascular conditions may lead to adverse 
effects. The SUSTAIN trial showed that although there is 
no link to myocardial infarction, a 10% incidence of stroke 
was found in patients with previous cerebrovascular dis-
ease that were also being treated with VEGF inhibiting 
medications (Stewart, 2012). In patients receiving regular 
treatment with ranibizumab, there was a higher incidence 
of heart attack, stroke, or death from cardiovascular or 
unknown conditions (Wells, 2016).
Finally, the nature of this treatment option for AMD/
DMR is that frequent, monthly follow up visits are re-
quired to monitor and readminister the drug, render-
ing compliance of treatment more difficult to upkeep. 
Inherent drawbacks to the use of VEGF inhibiting agents 
are its cost and frequency of treatment as it relates to 
burden on the patient. Perhaps lowering the overall cost 
of the treatment (medication and visit) while creating a 
medication with a longer half-life or efficacy will allow 
more patients to undergo long term treatment, prevent-
ing blindness (Baek et al., 2019). In some cases, the use 
of a laser to clear drusen and prevent the furthering of 
neovascularization may be more appropriate, as will now 
be discussed. 
Use of Pan Retinal Photocoagulation
Although traditional cases of diabetic retinopathy and 
macular degeneration now indicate treatment with in-
travitreal injections, this has not been the case for long. 
In the past, the first line of defense was treatment with 
blue-green Argon laser in order to create lesions around 
the area of retinal neovascularization and promote the 
regression of abnormal blood vessels and drusen. This 
option to help DMR and AMD is called pan retinal pho-
tocoagulation. In this technique, a beam of light from the 
laser is focused onto the retina using a special lens. The 
strength of the laser now used is usually weaker, with 
studies trying to determine the efficacy of subthreshold 
laser treatment to avoid applying more energy than nec-
essary. Up to 300 lesion spots may be delivered, with each 
one between 100μm and 200μm in size. “Subthreshold 
photocoagulation delivers light energy with very short 
impulses that are absorbed by the RPE only, aiming to 
spare the neurosensory retina”. Adjusting the strength, 
pulse duration, and frequency of the laser makes the 
treatment effective yet more gentle on the choroid in 
an attempt to reduce potential photoreceptor loss. 
Although the mechanism of treatment is not fully known, 
some ideas explain its efficiency. 
Firstly, the laser may help in clearing remnants left by 
phagocytic cells and macrophages along the choroid. It is 
hypothesized that the accumulation of these cells leads 
to the development of drusen. Another train of thought 
is that the laser may precipitate the RPE layer to release 
cytokines and growth factors that are able to “modify the 
biochemical processes underlying the clinical manifesta-
tions of the retinal disorder, rather than simply destroying 
drusen, and may also act on the drusen remote from the 
site of laser energy application” (Virgili et al., 2015). Also, 
the laser energy is capable of causing the temperature of 
the retina to rise slightly, leading to the release of heat 
shock proteins. They “act as chaperones for refolding mis-
folded proteins in aging cells, thereby rejuvenating retinal 
pigment epithelium (RPE) cells and restoring their cellular 
function” (Eng et al., 2019).
A study included patients with extrafoveal neovascular 
presentation with drusen. Patients were 50 years of age 
or older and visual acuity either was 20/100 or worse 
(Silva, 2011). The laser used was a conventional blue-
green Argon laser. Energy was set to be powerful enough 
to create the necessary lesions or controlled burns on 
neovascular areas. In this study, attention was not paid 
to maintaining sub-threshold energy. By using pan retinal 
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photocoagulation, the likelihood to stabilize the visual 
acuity of a patient doubled for those eyes, showing a 58% 
reduction in the risk to have severe vision loss. 
Highlights from the Macular Photocoagulation Study 
Group (Silva, 2011) are shown here:
A. Five years after treatment, average visual acuity 
was 20/125 in the group treated compared to 
20/200 in patients not treated with PRP.
B. Within the five-year span of treatment, 54% of 
patients had signs of recurring severe vision loss, 
with the majority of cases taking place within two 
years of treatment.
C. Smoking after PRP treatment was linked to accel-
erated recurrence of severe vision loss, as 85% of 
patients smoked more than 10 cigarettes per day 
compared to 51% in the non-smoking population.
An additional analysis of 12 studies of 2,481 eyes that 
were treated with subthreshold pan retinal photocoagu-
lation showed similar results. This study included treat-
ments done with 514nm and 810nm lasers. Conclusions 
of the review showed that pan retinal photocoagulation 
treatment is effective in reducing drusen count and 
thereby improving visual acuity in patients with dry AMD 
with the 810nm laser being consistently more effective. 
However, the study mentions that in order to obtain a 
significant improvement in visual acuity, the treatment 
must clear a substantial amount of drusen. Additionally, 
the study found that among the eyes that were treated, 
there was “no significant change in the risk of develop-
ing choroidal neovascularization or geographic atrophy” 
(Eng et al., 2019) and that more research would need 
to be done to conclusively confirm the efficacy of the 
810nm infrared diode laser compared to the 514nm laser. 
Comparing the treated patients with the observed 
patients in the study, the following data was obtained in 
regard to the relationship of diminishing drusen and treat-
ment with pan retinal photocoagulation (Eng et al., 2019): 
1. In five out of the 12 studies in which visual acuity 
was measured, it was determined that there was 
no difference in visual acuity in the groups who 
had and had not received treatment. Yet, the re-
maining studies showed a correlation between 
receiving treatment and improved visual acuity. 
This indicates that although pan retinal photoco-
agulation may be effective in clearing drusen from 
the retina, perhaps more research is necessary to 
conclude the effectiveness of the laser in improv-
ing the visual outcome for the patient.
2. In regard to the development of choroidal neo-
vascularization (CNV), three of nine studies that 
followed up on this mentioned that there was no 
development of CNV. An additional three howev-
er noted that eyes treated with subthreshold pan 
retinal photocoagulation were slightly more likely 
to develop CNV.
3. Geographic atrophy was also monitored in this 
series of studies. It was reported that two studies 
showed GA in treated eyes, while another study 
showed that although the incidence of developing 
geographic atrophy in treated eyes was 3.9%, the 
likelihood was higher in eyes that were not treat-
ed, at 14.0%.
After five years, following up on patients showed 64% 
of eyes that were not treated with the laser developed 
more severe vision loss compared to 46% of patients that 
had treatment with PRP. Yet, the recurrence rate of vision 
loss was 54%, with 75% of those recurrences taking place 
in the first year (Cook et al., 2008).
Conclusion
Currently, there are a number of available treatment 
options to reduce visual complaints and pathological 
findings in patients with chorioretinal vascular condi-
tions. Interventions such as subthreshold pan retinal 
photocoagulation and vascular endothelial growth factor 
inhibiting agents are still undergoing various studies, yet 
they do appear to be effective and promising options for 
patients battling age related macular degeneration and 
diabetic retinopathy. There are reasons why a clinician 
may choose one over the other in hopes of achieving 
the maximum benefit for the patient, depending on cost, 
compliance, and coexisting conditions. Although vascular 
endothelial growth factor inhibiting agents have become 
the first line of defense against neovascularization and 
other such complications of ocular disease, there are still 
reasons why they may not be the appropriate treatment 
option for a given patient as there are associated risks. 
Furthermore, some clinicians believe that using alterna-
tives such as PRP may be a better option altogether. On 
the other hand, an advantage of VEGF inhibiting agents 
over pan retinal photocoagulation is “prompt regression 
of neovascularization and the preservation of peripheral 
and night vision” (Buffolino & Park, 2019). Undergoing 
treatment with VEGF inhibiting medications for patients 
with severe vision loss may not be recommended as the 
drug may not be able to restore vision (Baek et al., 2019), 
however in most circumstances, VEGF inhibiting drugs can 
and perhaps should be implemented to alleviate both the 
visual complaints and the pathological dangers associat-
ed with chorioretinal vascular conditions. Potential risks 
previously discussed such as IOP elevation, inflammation, 
visual and pathological damage, and coexisting conditions 
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may need to be considered on a case by case basis, ne-
cessitating another modality of treatment. Nevertheless, 
it should be stressed that without a proper dilated exam, 
very little can be observed and treated; imaging methods 
can also be used to monitor the stability or progression 
of these diseases.
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